CSIMarket
 

Revolution Medicines Inc   (NASDAQ: RVMD)
Other Ticker:  
 

Revolution Medicines Inc 's

Competitiveness



 
 

RVMD Sales vs. its Competitors Q4 2024



Comparing the current results to its competitors, Revolution Medicines Inc reported Revenue decrease in the 4 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.12 %, recorded in the same quarter.

List of RVMD Competitors





Revenue Growth Comparisons




Net Income Comparison


Revolution Medicines Inc recorded a net loss, despite income increase by most of its competitors of 0 %

<<  RVMD Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Revolution Medicines Inc Contracts

Revolution Medicines Unveils Groundbreaking RAS Inhibitor with Unprecedented Anti-Tumor Activity in Pancreatic Cancer Models

April 8, 2024
Revolution Medicines Announces Groundbreaking Discovery and Preclinical Profile of New Class of RAS(ON) Multi-Selective Inhibitors with Unprecedented Anti-Tumor Activity in RAS-Mutant Pancreatic Cancer ModelsRevolution Medicines, a leading biotechnology company focused on developing innovative cancer treatments, has recently made significant progress in the field of oncology. In a press release issued today, the company announced the publication of two original papers in the prestigious scientific journal Nature, showcasing the discovery and translational implications of their latest breakthrough compound, RMC-7977.RMC-7977 is a RAS(ON) multi-selective tri-complex inhibitor, specifically designed to block th...





Publicly Traded Peers of Revolution Medicines Inc




Aceragen Inc
Share Performance



0.00%
One Year



Aceragen Inc
Profile

Aceragen Inc is a biotechnology company that follows a business model focused on the research, development, and commercialization of innovative gene-based therapies for treating genetic diseases. They aim to leverage their expertise in genetic medicine to create and deliver advanced therapies that address unmet medical needs and improve patient outcomes.

More about Aceragen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.831 mill. $ 7.332 mill. $ -41.049 mill.


Arcellx Inc
Share Performance



+12.28%
30 Days



Arcellx Inc
Profile

Arcellx Inc operates on a business model focused on developing and commercializing next-generation cell therapies for the treatment of various diseases by utilizing its proprietary ARC-SparX platform technology. The company intends to leverage its technology to create novel and improved therapies, targeting both liquid and solid tumors, aiming for better patient outcomes.

More about Arcellx Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,646.927 mill. $ 76.809 mill. $ -162.420 mill.


Alector Inc
Share Performance



+6.94%
Over The Past 5 Days



Alector Inc
Profile

Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.

More about Alector Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 153.073 mill. $ 88.339 mill. $ -123.441 mill.


Aligos Therapeutics Inc
Share Performance



+32.02%
30 Days



Aligos Therapeutics Inc
Profile

Aligos Therapeutics Inc's business model involves developing innovative therapeutics for the treatment of viral diseases.

More about Aligos Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 67.152 mill. $ 3.270 mill. $ -53.260 mill.


Allogene Therapeutics Inc
Share Performance



+20.72%
30 Days



Allogene Therapeutics Inc
Profile

Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.

More about Allogene Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 288.581 mill. $ - mill. $ -252.323 mill.


Ambrx Biopharma Inc
Share Performance



+0.21%
Over The Past 5 Days



Ambrx Biopharma Inc
Profile

Ambrx Biopharma Inc's business model can be described as a biopharmaceutical company that focuses on developing protein therapeutics through the use of its proprietary technology called ReCODE?.

More about Ambrx Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,743.012 mill. $ 8.602 mill. $ -134.113 mill.


Amgen Inc
Share Performance



+5.47%
30 Days



Amgen Inc
Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ 5,933.000 mill.


Apogee Therapeutics Inc
Share Performance



+10.84%
Over The Past 5 Days



Apogee Therapeutics Inc
Profile

Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.

More about Apogee Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,588.526 mill. $ - mill. $ -205.391 mill.


Aptose Biosciences Inc
Share Performance



-51.00%
Over The Past 5 Days



Aptose Biosciences Inc
Profile

Aptose Biosciences Inc has a business model focused on developing and commercializing targeted therapies for the treatment of various types of cancers. This involves conducting research, preclinical and clinical development activities, and eventually partnering or licensing their drug candidates to pharmaceutical companies for further development and commercialization.

More about Aptose Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.636 mill. $ - mill. $ -21.333 mill.


Armata Pharmaceuticals Inc
Share Performance



-4.59%
Over The Past 5 Days



Armata Pharmaceuticals Inc
Profile

Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.

More about Armata Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 111.225 mill. $ - mill. $ -0.426 mill.


Atara Biotherapeutics Inc
Share Performance



-37.71%
This Year



Atara Biotherapeutics Inc
Profile

Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.

More about Atara Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 95.706 mill. $ 303.057 mill. $ -15.641 mill.


Autolus Therapeutics Plc
Share Performance



-9.79%
Over The Past 5 Days



Autolus Therapeutics Plc
Profile

Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.

More about Autolus Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 564.188 mill. $ 9.011 mill. $ -238.133 mill.


Biocryst Pharmaceuticals Inc
Share Performance



-6.66%
Over The Past 5 Days



Biocryst Pharmaceuticals Inc
Profile

Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.

More about Biocryst Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,232.257 mill. $ 503.485 mill. $ -53.470 mill.


Biogen Inc
Share Performance



-4.89%
Over The Past 5 Days



Biogen Inc
Profile

Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.

More about Biogen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 18,553.696 mill. $ 9,816.400 mill. $ 1,479.300 mill.


Cullinan Therapeutics Inc
Share Performance



-4.65%
This Quarter



Cullinan Therapeutics Inc
Profile

Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.

More about Cullinan Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 507.172 mill. $ - mill. $ -178.736 mill.


Coherus Biosciences inc
Share Performance



-54.93%
One Year



Coherus Biosciences inc
Profile

Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.

More about Coherus Biosciences inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 88.249 mill. $ 197.496 mill. $ -130.937 mill.


Calidi Biotherapeutics Inc
Share Performance



-15.85%
30 Days



Calidi Biotherapeutics Inc
Profile

Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.

More about Calidi Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.766 mill. $ - mill. $ -22.209 mill.


Compass Therapeutics Inc
Share Performance



+14.76%
30 Days



Compass Therapeutics Inc
Profile

Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.

More about Compass Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 333.149 mill. $ - mill. $ -55.221 mill.


Cardiol Therapeutics inc
Share Performance



+6.57%
This Year



Cardiol Therapeutics inc
Profile

Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.

More about Cardiol Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 94.116 mill. $ - mill. $ -21.546 mill.


Cel sci Corporation
Share Performance



-81.71%
This Year



Cel sci Corporation
Profile

Cel-Sci Corporation's business model revolves around developing and commercializing immunotherapy drugs for the treatment of infectious diseases and certain types of cancer.

More about Cel sci Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.341 mill. $ - mill. $ -26.612 mill.


Dyadic International Inc
Share Performance



-45.98%
This Year



Dyadic International Inc
Profile

Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.

More about Dyadic International Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 28.093 mill. $ 3.554 mill. $ -5.827 mill.


Enzon Pharmaceuticals inc
Share Performance



0.00%
Over The Past 5 Days



Enzon Pharmaceuticals inc
Profile

Enzon Pharmaceuticals Inc. operates under a business model that focuses on the research, development, and commercialization of therapeutic drugs to address unmet medical needs. The company primarily employs a licensing strategy, partnering with other pharmaceutical companies to advance their drug candidates through clinical development and regulatory approval. By leveraging collaborations and out-licensing opportunities, Enzon aims to bring new therapies to market efficiently while maximizing shareholder value.

More about Enzon Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.501 mill. $ 1.723 mill. $ -0.066 mill.


Tradeup Acquisition Corp
Share Performance



-2.89%
Over The Past 5 Days



Tradeup Acquisition Corp
Profile

Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.

More about Tradeup Acquisition Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 34.741 mill. $ - mill. $ -6.955 mill.


Exelixis Inc
Share Performance



+91.31%
One Year



Exelixis Inc
Profile

Exelixis Inc's business model is focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer.

More about Exelixis Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11,985.281 mill. $ 2,298.922 mill. $ 1,481.629 mill.


Fate Therapeutics Inc
Share Performance



-16.12%
Over The Past 5 Days



Fate Therapeutics Inc
Profile

Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.

More about Fate Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 150.929 mill. $ 13.335 mill. $ -175.879 mill.


Fusion Pharmaceuticals Inc
Share Performance



+72.40%
This Quarter



Fusion Pharmaceuticals Inc
Profile

Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of targeted alpha therapeutics for the treatment of cancer. Their business model revolves around harnessing the power of radiation to selectively kill cancer cells while sparing healthy tissues. By combining targeted alpha therapy with various cancer-targeting agents, they aim to develop innovative treatments that offer improved efficacy and reduced side effects for patients.

More about Fusion Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,805.365 mill. $ - mill. $ -104.276 mill.


Gilead Sciences Inc
Share Performance



-1.19%
Over The Past 5 Days



Gilead Sciences Inc
Profile

Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.

More about Gilead Sciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 135,972.000 mill. $ 28,735.000 mill. $ 5,965.000 mill.


Gamida Cell Ltd
Share Performance



-88.89%
30 Days



Gamida Cell Ltd
Profile

Gamida Cell Ltd's business model is focused on developing and bringing innovative cell therapies to market for the treatment of various diseases, with a particular emphasis on hematological malignancies and serious blood disorders.

More about Gamida Cell Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.108 mill. $ 1.563 mill. $ 21.465 mill.


Genenta Science S p a
Share Performance



+1.17%
This Quarter



Genenta Science S p a
Profile

Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.

More about Genenta Science S p a 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -9.982 mill.


Halozyme Therapeutics Inc
Share Performance



+12.43%
This Year



Halozyme Therapeutics Inc
Profile

Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.

More about Halozyme Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6,836.243 mill. $ 1,084.306 mill. $ 485.363 mill.


Immunitybio inc
Share Performance



+8.10%
30 Days



Immunitybio inc
Profile

Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.

More about Immunitybio inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,619.207 mill. $ 31.222 mill. $ -409.181 mill.


In8bio Inc
Share Performance



-93.09%
One Year



In8bio Inc
Profile

In8bio Inc operates as a clinical-stage biotechnology company that focuses on developing transformative therapies for the treatment of cancer and other diseases. The company follows a research and development model centered on leveraging their proprietary platform to identify and optimize novel genetic circuits for targeted cell-based therapies.

More about In8bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 188.670 mill. $ - mill. $ -27.425 mill.


Iovance Biotherapeutics inc
Share Performance



-40.11%
This Quarter



Iovance Biotherapeutics inc
Profile

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

More about Iovance Biotherapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 723.224 mill. $ 212.679 mill. $ -375.364 mill.


Innate Pharma Sa
Share Performance



+1.34%
This Year



Innate Pharma Sa
Profile

Innate Pharma SA's business model revolves around the development and commercialization of innovative cancer immunotherapies.

More about Innate Pharma Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 159.391 mill. $ 69.038 mill. $ -8.478 mill.


Iteos Therapeutics Inc
Share Performance



-37.34%
One Year



Iteos Therapeutics Inc
Profile

Iteos Therapeutics Inc is a company that focuses on developing innovative immunotherapies to treat cancer by targeting the tumor microenvironment.

More about Iteos Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 439.764 mill. $ - mill. $ -130.811 mill.


Jasper Therapeutics Inc
Share Performance



+13.18%
30 Days



Jasper Therapeutics Inc
Profile

Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.

More about Jasper Therapeutics Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 83.823 mill. $ - mill. $ -78.782 mill.


Ladrx Corporation
Share Performance



0.00%
30 Days



Ladrx Corporation
Profile

Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.

More about Ladrx Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.738 mill. $ - mill. $ -1.590 mill.


Lexeo Therapeutics Inc
Share Performance



-10.05%
Over The Past 5 Days



Lexeo Therapeutics Inc
Profile

Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.

More about Lexeo Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 130.469 mill. $ - mill. $ -109.307 mill.


Mesoblast Ltd
Share Performance



-10.69%
This Quarter



Mesoblast Ltd
Profile

Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.

More about Mesoblast Ltd's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11,628.751 mill. $ 5.902 mill. $ -87.956 mill.


Molecular Partners Ag
Share Performance



-43.28%
One Year



Molecular Partners Ag
Profile

Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.

More about Molecular Partners Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 125.839 mill. $ 7.038 mill. $ -61.984 mill.


Orchard Therapeutics Plc
Share Performance



+4.44%
This Quarter



Orchard Therapeutics Plc
Profile

Orchard Therapeutics Plc operates as a biotechnology company specializing in gene therapies for rare diseases. Their business model involves developing and commercializing potentially curative gene therapies to address the underlying cause of these diseases. They collaborate with academic and industry partners to advance their research and utilize their expertise to bring innovative therapies to patients in need.

More about Orchard Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,814.089 mill. $ 21.839 mill. $ -72.921 mill.


Phoenix Biotech Acquisition Corp
Share Performance



0.00%
30 Days



Phoenix Biotech Acquisition Corp
Profile

Phoenix Biotech Acquisition Corp is a company that focuses on acquiring and investing in biotech businesses.

More about Phoenix Biotech Acquisition Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 35.544 mill. $ - mill. $ -10.041 mill.


Biomx Inc
Share Performance



-24.26%
30 Days



Biomx Inc
Profile



More about Biomx Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9.449 mill. $ - mill. $ 8.059 mill.


Peak Bio Inc
Share Performance



0.00%
This Quarter



Peak Bio Inc
Profile

Peak Bio Inc is a biotechnology company specializing in the development and commercialization of innovative medical products. Their business model focuses on conducting extensive research and development to create cutting-edge biopharmaceuticals. These products are then marketed and distributed to healthcare providers and patients, aiming to improve patient outcomes and contribute to advancements in the healthcare industry.

More about Peak Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.422 mill. $ - mill. $ -3.324 mill.


Mosaic Immunoengineering Inc
Share Performance



0.00%
One Year



Mosaic Immunoengineering Inc
Profile

Mosaic Immunoengineering Inc's business model revolves around leveraging cutting-edge technologies and expertise in immunoengineering to develop innovative solutions and therapies for immune-related diseases.

More about Mosaic Immunoengineering Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.037 mill. $ - mill. $ -0.815 mill.


Sab Biotherapeutics Inc
Share Performance



-9.09%
Over The Past 5 Days



Sab Biotherapeutics Inc
Profile

Sab Biotherapeutics Inc's business model focuses on developing and producing innovative antibody therapeutics using advanced genetic engineering techniques.

More about Sab Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15.796 mill. $ - mill. $ -34.276 mill.


Scinai Immunotherapeutics Ltd
Share Performance



-35.47%
This Year



Scinai Immunotherapeutics Ltd
Profile



More about Scinai Immunotherapeutics Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,469.033 mill. $ - mill. $ 6.500 mill.


Seagen Inc
Share Performance



+4.77%
Over The Past 5 Days



Seagen Inc
Profile

Seagen Inc is a biotechnology company that focuses on developing and commercializing innovative cancer therapeutics. Their business model revolves around research and development of targeted antibody-based drugs, specifically using their proprietary antibody-drug conjugate (ADC) technology. Seagen Inc also seeks strategic collaborations and partnerships with other pharmaceutical companies to enhance their product pipeline and expand their market reach.

More about Seagen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 43,034.000 mill. $ 2,300.351 mill. $ -750.225 mill.


Sorrento Therapeutics Inc
Share Performance



+230.00%
Over The Past 5 Days



Sorrento Therapeutics Inc
Profile

Sorrento Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for various diseases, including cancer, autoimmune disorders, and pain management.

More about Sorrento Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 18.192 mill. $ 48.676 mill. $ -353.787 mill.


Sutro Biopharma Inc
Share Performance



-6.45%
30 Days



Sutro Biopharma Inc
Profile

Sutro Biopharma Inc has a business model focused on developing and commercializing innovative antibody-based therapeutics.

More about Sutro Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 69.950 mill. $ 66.434 mill. $ -245.216 mill.


Springworks Therapeutics Inc
Share Performance



+29.48%
One Year



Springworks Therapeutics Inc
Profile

Springworks Therapeutics Inc is a biopharmaceutical company with a focus on developing innovative medicines for underserved patient populations. Their business model revolves around identifying promising therapeutic candidates, which could address significant unmet needs, and advancing them through various stages of clinical development. They collaborate with academic institutions, research organizations, and industry partners to accelerate the discovery and development of potential treatments, ultimately aiming to bring these therapies to market and improve patient outcomes.

More about Springworks Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -258.131 mill.


Tscan Therapeutics Inc
Share Performance



-81.55%
One Year



Tscan Therapeutics Inc
Profile

Tscan Therapeutics Inc is a biotechnology company that focuses on developing and commercializing T cell receptor therapies for cancer patients. Their business model revolves around leveraging their T cell platform to develop innovative treatments and secure partnerships with other pharmaceutical companies for clinical development and commercialization.

More about Tscan Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 201.002 mill. $ 4.421 mill. $ -131.484 mill.


Turnstone Biologics Corp
Share Performance



-38.06%
This Year



Turnstone Biologics Corp
Profile

Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.

More about Turnstone Biologics Corp 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 7.740 mill. $ - mill. $ -63.014 mill.


Tevogen Bio Holdings Inc
Share Performance



+16.98%
This Year



Tevogen Bio Holdings Inc
Profile



More about Tevogen Bio Holdings Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 181.991 mill. $ - mill. $ -10.274 mill.


Vir Biotechnology Inc
Share Performance



+13.48%
30 Days



Vir Biotechnology Inc
Profile

Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.

More about Vir Biotechnology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 717.588 mill. $ 20.861 mill. $ -577.649 mill.


Zura Bio Limited
Share Performance



-15.85%
This Quarter



Zura Bio Limited
Profile

Zura Bio Limited operates on a business model focused on developing and commercializing innovative bio-based solutions.

More about Zura Bio Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 111.092 mill. $ - mill. $ -62.098 mill.


Astrazeneca Plc
Share Performance



+8.15%
30 Days



Astrazeneca Plc
Profile

AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.

More about Astrazeneca Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 116,244.040 mill. $ 45,811.000 mill. $ 5,961.000 mill.


Black Diamond Therapeutics Inc
Share Performance



+35.09%
This Quarter



Black Diamond Therapeutics Inc
Profile

Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.

More about Black Diamond Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 133.225 mill. $ 70.000 mill. $ 5.091 mill.


Bristol myers Squibb Company
Share Performance



-16.85%
This Year



Bristol myers Squibb Company
Profile

Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.

More about Bristol myers Squibb Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 96,643.600 mill. $ 47,636.000 mill. $ 5,437.000 mill.


Merck and Co Inc
Share Performance



-2.54%
Over The Past 5 Days



Merck and Co Inc
Profile

Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.

More about Merck and Co Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 197,803.045 mill. $ 63,922.000 mill. $ 17,451.000 mill.


Mural Oncology Plc
Share Performance



-5.75%
Over The Past 5 Days



Mural Oncology Plc
Profile

Mural Oncology Plc's business model focuses on developing and commercializing innovative cancer therapies. They likely collaborate with research institutes and pharmaceutical companies to acquire promising drug candidates and conduct rigorous clinical trials. Their revenue is generated through licensing, partnerships, and potential product sales, helping provide solutions for patients suffering from various forms of cancer.

More about Mural Oncology Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 42.235 mill. $ - mill. $ -130.734 mill.


Novartis Ag
Share Performance



+12.99%
One Year



Novartis Ag
Profile

Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.

More about Novartis Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 249,889.400 mill. $ 46,660.000 mill. $ 14,854.000 mill.


Pfizer Inc
Share Performance



-8.45%
This Quarter



Pfizer Inc
Profile

Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.

More about Pfizer Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 137,011.450 mill. $ 62,463.000 mill. $ 7,912.000 mill.




Sources: Revolution Medicines Inc and all companies mentioned above in this report


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com